Difference between revisions of "Main Page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "http://en.wikipedia.org" to "https://en.wikipedia.org")
 
(189 intermediate revisions by 2 users not shown)
Line 6: Line 6:
 
</div>
 
</div>
  
−
{| border="1"; style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
+
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div>
 +
 
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
|-
 
|-
−
|colspan="2" style="background-color:#F0F0F0"|'''[[Tutorial#Regimens|Regimens]]:<big> {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}</big>'''
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,262
−
|colspan="2" style="background-color:#F0F0F0"|'''[[Tutorial#Variant|Regimen variants]]:<big> {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}</big>'''
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:#3c0008;">Guidelines: 1,217</span>
 +
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6,769
 +
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7,731
 
|-
 
|-
−
|style="width: 25%; border-left:solid 20px #3182bd; background-color:#deebf7"|[[#solidtumors|Solid Tumors]]
+
|}
−
|style="width: 25%; border-left:solid 20px #de2d26; background-color:#fee0d2"|[[#malignantheme|Malignant Hematology]]
+
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
−
|style="width: 25%; border-left:solid 20px #756bb1; background-color:#efedf5"|[[#transplant|Transplant]]
 
−
|style="width: 25%; border-left:solid 20px #31a354; background-color:#e5f5e0"|[[#classicalheme|Classical Hematology]]
 
 
|-
 
|-
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
+
|style="width: 20%; font-size:125%; background-color:#08519c"|[[#solidtumors|<span style="color:white;">Solid Tumors</span>]]
−
|colspan="2" style="background-color:#F0F0F0"|<big>[[Editorial Board]]</big>
+
|style="width: 20%; font-size:125%; background-color:#de2d26"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]]
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]'''
+
|style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]]
−
|-
+
|style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant & IEC</span>]]
−
|[[:Category:Disease index|Disease index]]
+
|style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]]
−
|[[:Category:Drug index|Drug index]]
 
−
|[[:Category:Regimen index|Regimen index]]
 
−
|[[:Category:General reference pages|General reference]]
 
 
|-
 
|-
 
|}  
 
|}  
−
 
−
<div style="text-align:center"><big>'''If this is your first time visiting, please [[Tutorial|go to the tutorial page]] or just start exploring!'''</big></div>
 
  
 
==Links to all main disease pages==
 
==Links to all main disease pages==
 
<span id="solidtumors"></span>
 
<span id="solidtumors"></span>
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
+
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#3182bd"| '''Solid Tumors'''
+
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#08519c"| '''Solid Tumors'''
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Breast Oncology'''
 +
|-
 +
|style="background-color:#deebf7"|[[Breast cancer]]
 +
|style="background-color:#deebf7"|[[Breast cancer, ER-positive]]
 +
|style="background-color:#deebf7"|[[Breast cancer, HER2-positive]]
 +
|style="background-color:#deebf7"|[[Breast cancer, ER and HER2 co-expressing]]
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Breast Oncology'''
+
|style="background-color:#deebf7"|[[Breast cancer, triple negative|Breast cancer, triple negative (TNBC)]]
 +
|style="background-color:#deebf7"|[[Breast cancer, BRCA-mutated]]
 +
|style="background-color:#deebf7"|[[Breast cancer, PIK3CA-mutated]]
 +
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Breast cancer]]
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Dermatologic Oncology'''
−
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Breast cancer, HER-2 positive]]
 
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Dermatologic Oncology'''
+
|style="background-color:#deebf7"|[[Cutaneous basal cell carcinoma | Cutaneous BCC]]
 +
|style="background-color:#deebf7"|[[Cutaneous squamous cell carcinoma | Cutaneous SCC]]
 +
|style="background-color:#deebf7"|[[Melanoma]]
 +
|style="background-color:#deebf7"|[[Melanoma,_BRAF-mutated|Melanoma, BRAF-mutated]]
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Melanoma]]  
+
|style="background-color:#deebf7"|[[Melanoma,_KIT-mutated|Melanoma, KIT-mutated]]  
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]]
+
|style="background-color:#deebf7"|[[Melanoma,_NRAS-mutated|Melanoma, NRAS-mutated]]  
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Merkel cell carcinoma]]  
+
|style="background-color:#deebf7"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]  
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
+
|style="background-color:#deebf7"|[[Uveal melanoma]]  
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Endocrine Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Endocrine Oncology'''
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Adrenocortical carcinoma]]
+
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Neuroendocrine tumors]]
+
|style="background-color:#deebf7"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Pancreatic NET]]
+
|style="background-color:#deebf7"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Pheochromocytoma]]
+
|style="background-color:#deebf7"|[[Pancreatic NET]]
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Thyroid cancer]]
+
|style="background-color:#deebf7"|[[Pheochromocytoma]]
−
|style="background-color:#deebf7"|
+
|style="background-color:#deebf7"|[[Thyroid cancer]]
 +
|style="background-color:#deebf7"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
 +
|style="background-color:#deebf7"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
 +
|-
 +
|style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]]
 +
|style="background-color:#deebf7"|[[Thyroid_cancer,_RET-positive|Thyroid cancer, RET-positive]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Gastrointestinal Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Intestinal'''
 +
|-
 +
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
 +
|style="width: 25%; background-color:#deebf7"|[[Appendiceal tumor]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colon cancer]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colon cancer, RAS wild-type]]
 +
|-
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer|Colorectal cancer (CRC)]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, BRAF-mutated|CRC, BRAF-mutated]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, HER2-positive|CRC, HER2-positive]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, MSI-H or dMMR|CRC, MSI-H or dMMR]]
 +
|-
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, RAS wild-type|CRC, RAS wild-type]]
 +
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
 +
|style="width: 25%; background-color:#deebf7"|[[Esophageal adenocarcinoma]]
 +
|style="width: 25%; background-color:#deebf7"|[[Esophageal squamous cell carcinoma|Esophageal SCC]]
 +
|-
 +
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer]]
 +
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]]
 +
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
 +
|style="width: 25%; background-color:#deebf7"|[[Small bowel adenocarcinoma]]
 
|-
 
|-
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Anal cancer]]
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Extraintestinal'''
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Cholangiocarcinoma]]
 
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Colon cancer]]
 
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Esophageal cancer]]
 
 
|-
 
|-
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Gastric cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Cholangiocarcinoma]]
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="width: 25%; background-color:#deebf7"|[[Gallbladder cancer]]
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Hepatocellular carcinoma]]
+
|style="width: 25%; background-color:#deebf7"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Periampullary adenocarcinoma]]
+
|style="width: 25%; background-color:#deebf7"|[[Periampullary adenocarcinoma]]
 
|-
 
|-
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Pancreatic cancer]]  
+
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]]  
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Pancreatic NET]]
+
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated|Pancreatic adenocarcinoma, BRCA-mutated]]
−
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Rectal cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Genitourinary Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Bladder cancer]]
+
|style="background-color:#deebf7"|[[Penile cancer]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Penile cancer]]
+
|style="background-color:#deebf7"|[[Prostate cancer]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Prostate cancer]]
+
|style="background-color:#deebf7"|[[Prostate cancer, BRCA-mutated]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Renal cancer|Renal cancer (RCC)]]
+
|style="background-color:#deebf7"|[[Testicular cancer]]
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Testicular cancer]]
+
|style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
 +
|style="background-color:#deebf7"|[[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]]
 +
|style="background-color:#deebf7"|[[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]]
 +
|style="background-color:#deebf7"|[[Papillary renal cell carcinoma|Papillary RCC]]
 +
|-
 +
|style="background-color:#deebf7"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
 +
|style="background-color:#deebf7"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
 +
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 +
|-
 +
|style="background-color:#deebf7"|[[Urothelial carcinoma]]
 +
|style="background-color:#deebf7"|[[Bladder cancer]]
 +
|style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology'''
 +
|-
 +
|style="background-color:#deebf7"|[[Cervical cancer]]
 +
|style="background-color:#deebf7"|[[Endometrial cancer]]
 +
|style="background-color:#deebf7"|[[Gestational trophoblastic neoplasia]]
 +
|style="background-color:#deebf7"|[[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]]
 +
|-
 +
|style="background-color:#deebf7"|[[Ovarian cancer]]
 +
|style="background-color:#deebf7"|[[Ovarian cancer, BRCA-mutated]]
 +
|style="background-color:#deebf7"|[[Vulvar cancer]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Gynecologic Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Head & Neck Oncology'''
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Cervical cancer]]
+
|style="background-color:#deebf7"|[[Head and neck cancer]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Ovarian cancer]]
+
|style="background-color:#deebf7"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Uterine cancer]]
+
|style="background-color:#deebf7"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Head & Neck Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
 
|-
 
|-
−
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Head and neck cancer]]
+
|colspan="2" style="background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
−
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Thyroid cancer]]
+
|colspan="2" style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Neuro-Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Anaplastic glioma]]
+
|style="background-color:#deebf7"|[[Anaplastic glioma]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Glioblastoma]]
+
|style="background-color:#deebf7"|[[Craniopharyngioma]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Low-grade glioma]]
+
|style="background-color:#deebf7"|[[Glioblastoma|Glioblastoma (GBM)]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Meningioma]]
+
|style="background-color:#deebf7"|[[Low-grade glioma]]
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[CNS leukemia]]
+
|style="background-color:#deebf7"|[[Meningioma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[CNS lymphoma]]
+
|style="background-color:#deebf7"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Pediatric Oncology'''
+
|style="background-color:#deebf7"|[[CNS carcinoma]]
 +
|style="background-color:#deebf7"|[[CNS leukemia]]
 +
|style="background-color:#deebf7"|[[CNS lymphoma]]
 +
|style="background-color:#deebf7"|[[CNS melanoma]]
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Sarcoma'''
 +
|-
 +
|style="background-color:#deebf7"|[[Bone sarcoma]]
 +
|style="background-color:#deebf7"|[[Ewing sarcoma]]
 +
|style="background-color:#deebf7"|[[Giant-cell tumor of bone]]
 +
|style="background-color:#deebf7"|[[Osteosarcoma]]
 
|-
 
|-
−
|colspan="4" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Neuroblastoma]]
+
|style="background-color:#deebf7"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS)]]
 +
|style="background-color:#deebf7"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]]
 +
|style="background-color:#deebf7"|[[Dermatofibrosarcoma protuberans]]
 +
|style="background-color:#deebf7"|[[Desmoid tumor]]
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Sarcoma'''
+
|style="background-color:#deebf7"|[[Epithelioid sarcoma]]
 +
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
 +
|style="background-color:#deebf7"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]]
 +
|style="background-color:#deebf7"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]]
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Bone cancer]]  
+
|style="background-color:#deebf7"|[[Liposarcoma]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Ewing's sarcoma]]
+
|style="background-color:#deebf7"|[[PEComa]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="background-color:#deebf7"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Osteosarcoma]]
+
|style="background-color:#deebf7"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]]
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Sarcoma]]  
+
|style="background-color:#deebf7"|[[Vascular sarcoma]]
 +
|style="background-color:#deebf7"|[[Angiosarcoma]]
 +
|style="background-color:#deebf7"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology'''
 +
|-
 +
|style="background-color:#deebf7"|[[Non-small cell lung cancer | Non-small cell lung cancer (NSCLC)]]
 +
|style="background-color:#deebf7"|[[Non-small cell lung cancer, nonsquamous|NSCLC, nonsquamous]]
 +
|style="background-color:#deebf7"|[[Non-small cell lung cancer, squamous|NSCLC, squamous]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ALK-positive|NSCLC, ALK-positive]]
 +
|-
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_BRAF-mutated|NSCLC, BRAF-mutated]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_EGFR-mutated|NSCLC, EGFR-mutated]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_HER2-mutated|NSCLC, HER2-mutated]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_KRAS-mutated|NSCLC, KRAS-mutated]]
 +
|-
 +
|style="background-color:#deebf7"|[[Non-small cell lung cancer, MET-mutated|NSCLC, MET-mutated]]
 +
|style="background-color:#deebf7"|[[Non-small cell lung cancer, RET-positive|NSCLC, RET-positive]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ROS1-positive|NSCLC, ROS1-positive]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_CNS_metastases|NSCLC, CNS metastases]]
 +
|-
 +
|style="background-color:#deebf7"|[[Small cell lung cancer |Small cell lung cancer (SCLC)]]
 +
|style="background-color:#deebf7"|[[Thymoma]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Thoracic Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Site-agnostic'''
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Esophageal cancer]]
+
|style="background-color:#deebf7"|[[BRAF]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
+
|style="background-color:#deebf7"|[[EGFR]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
+
|style="background-color:#deebf7"|[[ERBB2 (HER2)]]
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Mesothelioma]]
+
|style="background-color:#deebf7"|[[ERBB3 (HER3)]]
 
|-
 
|-
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Thymoma]]
+
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
−
|style="background-color:#deebf7"|
+
|style="background-color:#deebf7"|[[NTRK]]
 +
|style="background-color:#deebf7"|[[RET]]
 +
|style="background-color:#deebf7"|[[SMO or PTCH-1 (Hedgehog)]]
 +
|-
 +
|style="background-color:#deebf7"|[[TMB-H]]
 +
|style="background-color:#deebf7"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Site-agnostic'''
 
−
|-
 
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[MSI-H or dMMR]]
 
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Adenocarcinoma of unknown primary]]
 
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[NET of unknown primary]]
 
−
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[SCC of unknown primary]]
 
 
|-
 
|-
 
|}
 
|}
 
<span id="malignantheme"></span>
 
<span id="malignantheme"></span>
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
 
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
 
|-
 
|-
−
|[[#top|back to top]]
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Acute leukemias'''
−
|}
+
|-
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
+
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
+
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
 +
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
 +
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Acute leukemias'''
+
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
 +
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
 +
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
 +
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
 
|-
 
|-
−
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
+
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
−
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
+
|style="background-color:#fee0d2"|[[CNS leukemia]]
−
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
+
|style="background-color:#fee0d2"|
−
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]]
+
|style="background-color:#fee0d2"|
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
+
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
+
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
+
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
+
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Myelodysplastic syndrome]]
+
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
+
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
+
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Systemic mastocytosis]]
+
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Aggressive lymphomas'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Aggressive lymphomas'''
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
+
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[CNS lymphoma]]
+
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
+
|style="background-color:#fee0d2"|[[CNS lymphoma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[HIV-associated lymphoma]]
+
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]  
+
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
+
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
+
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
+
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
+
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
 +
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Indolent lymphomas'''
 +
|-
 +
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]]
 +
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
 +
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
 +
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
 +
|-
 +
|style="background-color:#fee0d2"|[[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]]
 +
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
 +
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Indolent lymphomas'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Plasma cell dyscrasias'''
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL/SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
+
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
+
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
+
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
+
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
+
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
+
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
 +
|style="background-color:#fee0d2"|[[POEMS syndrome]]
 +
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
 +
|-
 +
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
 +
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
 +
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
 +
|style="background-color:#fee0d2"|[[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]]
 +
|-
 +
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
 +
|style="background-color:#fee0d2"|[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]
 +
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
 +
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
 +
|-
 +
|style="background-color:#fee0d2"|[[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]]
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 +
|style="background-color:#fee0d2"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Lymphoproliferative disorders'''
 +
|-
 +
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
 +
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
 +
|-
 +
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
 +
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
 +
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]
 +
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
 +
|-
 +
|}
 +
<span id="peds"></span>
 +
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#ba871a"|'''Pediatric Neoplasms'''
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Plasma cell dyscrasias'''
+
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric CNS malignancies'''
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
+
|style="width: 25%; background-color:#e8d7b3"|[[Low-grade glioma, pediatric|Low-grade glioma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (MM)]]
+
|style="width: 25%; background-color:#e8d7b3"|[[High-grade glioma, pediatric|High-grade glioma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Plasma cell leukemia]]
+
|style="width: 25%; background-color:#e8d7b3"|[[Medulloblastoma]]
−
|style="background-color:#fee0d2"|
+
|style="width: 25%; background-color:#e8d7b3"|
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
+
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric hematologic neoplasms'''
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
+
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
+
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
+
|style="background-color:#e8d7b3"|[[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Extranodal NK/T-cell lymphoma, nasal type]]
+
|style="background-color:#e8d7b3"|[[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]]
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
+
|style="background-color:#e8d7b3"|[[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[NK/T-cell lymphoma]]
+
|style="background-color:#e8d7b3"|[[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
+
|style="background-color:#e8d7b3"|[[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]]
−
|style="background-color:#fee0d2"|
+
|style="background-color:#e8d7b3"|
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Lymphoproliferative disorders'''
+
|style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]]
 +
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]]
 +
|style="background-color:#e8d7b3"|
 +
|style="background-color:#e8d7b3"|
 
|-
 
|-
−
|colspan="2" style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Castleman disease]]
+
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric solid tumors'''
−
|colspan="2" style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Histiocyte disorders'''
+
|style="background-color:#e8d7b3"|[[Epithelioid sarcoma]]
 +
|style="background-color:#e8d7b3"|[[Ewing sarcoma, pediatric|Ewing sarcoma]]
 +
|style="background-color:#e8d7b3"|[[Hepatoblastoma]]
 +
|style="background-color:#e8d7b3"|[[Neuroblastoma]]
 
|-
 
|-
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Erdheim-Chester disease]]
+
|style="background-color:#e8d7b3"|[[Osteosarcoma, pediatric|Osteosarcoma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
+
|style="background-color:#e8d7b3"|[[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]]
−
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Langerhans cell histiocytosis]]
+
|style="background-color:#e8d7b3"|[[Wilms tumor]]
−
|style="background-color:#fee0d2"|
+
|style="background-color:#e8d7b3"|
 
|-
 
|-
 
|}
 
|}
 
<span id="transplant"></span>
 
<span id="transplant"></span>
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
 
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant and Immune Effector Cells (IECs)'''
 
|-
 
|-
−
|[[#top|back to top]]
+
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
−
|}
+
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]]
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
+
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]]
−
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#756bb1"|'''Transplant'''
+
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]]
 
|-
 
|-
−
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Stem cell mobilization]]
+
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
−
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Allogeneic HSCT]]
+
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]]
−
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Autologous HSCT]]
+
|style="background-color:#efedf5"|
−
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Graft versus host disease (GVHD)]]
+
|style="background-color:#efedf5"|
 
|-
 
|-
 
|}
 
|}
 
<span id="classicalheme"></span>
 
<span id="classicalheme"></span>
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
 
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
 
|-
 
|-
−
|[[#top|back to top]]
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemostasis and thrombosis'''
−
|}
+
|-
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
+
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
−
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
+
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]]
 +
|-
 +
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]]
 +
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
 +
|-
 +
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
 +
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
 +
|style="background-color:#e5f5e0"|
 +
|style="background-color:#e5f5e0"|
 
|-
 
|-
−
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Aplastic anemia]]
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
−
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
 
−
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Autoimmune cytopenias]]
 
−
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Autoimmune thrombocytopenic purpura (ITP)]]
 
 
|-
 
|-
−
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Coagulopathies]]
+
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
−
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Cold agglutinin disease]]
+
|style="background-color:#e5f5e0"|[[Autoimmune cytopenia]]
−
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]]
+
|style="background-color:#e5f5e0"|[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]
−
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Sickle cell anemia]]
+
|style="background-color:#e5f5e0"|[[Thrombocytopenia in liver disease]]
 
|-
 
|-
−
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
+
|style="background-color:#e5f5e0"|[[WHIM syndrome]]
−
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]]
+
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 +
|style="background-color:#e5f5e0"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies'''
 +
|-
 +
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
 +
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]
 +
|style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]
 +
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
 +
|-
 +
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]]
 +
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
 +
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|-
 
|-
Line 277: Line 451:
  
 
==Additional Information==
 
==Additional Information==
−
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes [[how to contribute|continuous peer review]].
+
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].
 +
 
 +
Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
 +
 
 +
Priorities of this project include:
 +
<section begin=goals />
 +
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
 +
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
 +
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
 +
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
 +
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
 +
<section end=goals />
 +
 
 +
Additional possibilities for this project may include:
 +
*Creating synopses of pivotal clinical trials and regimens
 +
*Prioritizing regimens by their efficacy and/or toxicity
 +
*Capturing historical regimens that were standard-of-care prior to 2005
 +
*Checklists for common clinical scenarios/diseases
 +
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 +
 
 +
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
  
 
<br><inputbox>
 
<br><inputbox>
Line 284: Line 478:
 
placeholder=Type the name of the page you want to create  
 
placeholder=Type the name of the page you want to create  
 
break=no  
 
break=no  
−
</inputbox>
+
</inputbox>
−
Any information that one feels would be helpful to other oncology providers is welcome.  Visit [[how to contribute]] for more details.  Priorities of this project include:
 
−
 
 
−
#Creating a database of [[Drug index | chemotherapy agents and other medications]].
 
−
#Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
 
−
#[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
 
−
#Aggregating [[External links|useful links]] to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.
 
−
 
 
−
Additional possibilities for this project may include:
 
−
#Creating summaries of pivotal clinical trials
 
−
#Establishing homepages for ongoing clinical trials that contain information and sites of participation
 
−
#Checklists for common clinical scenarios/diseases
 
−
#Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 
−
 
 
−
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource.  The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access.  We believe that the familiar format of a Wiki, made popular by sites such as [http://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
 

Latest revision as of 01:43, 26 June 2024


HemOnc.org - A Free Hematology/Oncology Reference

HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the the tutorial page, review our philosophy, or just start exploring!
Regimens: 5,262 Guidelines: 1,217 Studies: 6,769 References: 7,731
Solid Tumors Malignant Hematology Pediatrics Transplant & IEC Classical Hematology

Links to all main disease pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, ER-positive Breast cancer, HER2-positive Breast cancer, ER and HER2 co-expressing
Breast cancer, triple negative (TNBC) Breast cancer, BRCA-mutated Breast cancer, PIK3CA-mutated
Dermatologic Oncology
Cutaneous BCC Cutaneous SCC Melanoma Melanoma, BRAF-mutated
Melanoma, KIT-mutated Melanoma, NRAS-mutated Merkel cell carcinoma (MCC) Uveal melanoma
Endocrine Oncology
Adrenocortical carcinoma Neuroendocrine tumor (NET) Neuroendocrine carcinoma (NEC) Pancreatic NET
Pheochromocytoma Thyroid cancer Differentiated thyroid cancer (DTC) Medullary thyroid cancer (MTC)
Thyroid cancer, BRAF-mutated Thyroid cancer, RET-positive
Gastrointestinal Oncology, Intestinal
Anal cancer Appendiceal tumor Colon cancer Colon cancer, RAS wild-type
Colorectal cancer (CRC) CRC, BRAF-mutated CRC, HER2-positive CRC, MSI-H or dMMR
CRC, RAS wild-type Esophageal cancer Esophageal adenocarcinoma Esophageal SCC
Gastric cancer Gastric cancer, HER2-positive Rectal cancer Small bowel adenocarcinoma
Gastrointestinal Oncology, Extraintestinal
Cholangiocarcinoma Gallbladder cancer Hepatocellular carcinoma (HCC) Periampullary adenocarcinoma
Pancreatic adenocarcinoma Pancreatic adenocarcinoma, BRCA-mutated Pancreatic NET
Genitourinary Oncology
Penile cancer Prostate cancer Prostate cancer, BRCA-mutated Testicular cancer
Renal cell carcinoma (RCC) Clear cell RCC (ccRCC) Non-clear cell RCC (nccRCC) Papillary RCC
Sarcomatoid RCC VHL-associated RCC
Urothelial carcinoma Bladder cancer Upper tract urothelial carcinoma (UTUC)
Gynecologic Oncology
Cervical cancer Endometrial cancer Gestational trophoblastic neoplasia Low-grade serous ovarian cancer (LGSOC)
Ovarian cancer Ovarian cancer, BRCA-mutated Vulvar cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma (NPC) HPV+ Oropharyngeal cancer
Mesothelioma
Malignant peritoneal mesothelioma (MPEM) Malignant pleural mesothelioma (MPM)
Neuro-Oncology
Anaplastic glioma Craniopharyngioma Glioblastoma (GBM) Low-grade glioma
Meningioma Subependymal giant cell astrocytoma (SEGA)
CNS carcinoma CNS leukemia CNS lymphoma CNS melanoma
Sarcoma
Bone sarcoma Ewing sarcoma Giant-cell tumor of bone Osteosarcoma
Soft tissue sarcoma (STS) Alveolar soft part sarcoma (ASPS) Dermatofibrosarcoma protuberans Desmoid tumor
Epithelioid sarcoma Gastrointestinal stromal tumor (GIST) Inflammatory myofibroblastic tumor (IMT) Leiomyosarcoma (LMS)
Liposarcoma PEComa Rhabdomyosarcoma (RMS) Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma Angiosarcoma Kaposi sarcoma (KS)
Thoracic Oncology
Non-small cell lung cancer (NSCLC) NSCLC, nonsquamous NSCLC, squamous NSCLC, ALK-positive
NSCLC, BRAF-mutated NSCLC, EGFR-mutated NSCLC, HER2-mutated NSCLC, KRAS-mutated
NSCLC, MET-mutated NSCLC, RET-positive NSCLC, ROS1-positive NSCLC, CNS metastases
Small cell lung cancer (SCLC) Thymoma
Site-agnostic
BRAF EGFR ERBB2 (HER2) ERBB3 (HER3)
MSI-H or dMMR NTRK RET SMO or PTCH-1 (Hedgehog)
TMB-H Carcinoma of unknown primary (CUP)

Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated AML, NPM1-mutated
Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS) Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma Classical Hodgkin lymphoma (cHL) CNS lymphoma Diffuse large B-cell lymphoma (DLBCL)
High-grade B-cell lymphoma HIV-associated lymphoma Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL)
Primary mediastinal B-cell lymphoma (PMBL) Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
MALT lymphoma Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (main page) MM, induction MM, consolidation & maintenance
MM, relapsed/refractory Plasma cell leukemia (PCL) POEMS syndrome Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
Large granular lymphocytic (LGL) leukemia NK- and T-cell lymphoma (NKTCL) Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocytic disorders
Erdheim-Chester disease (ECD) Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis (LCH) Rosai-Dorfman-Destombes disease

Pediatric Neoplasms
Pediatric CNS malignancies
Low-grade glioma High-grade glioma Medulloblastoma
Pediatric hematologic neoplasms
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) Acute myeloid leukemia (AML)
Anaplastic large cell lymphoma (ALCL) Chronic myeloid leukemia (CML) Juvenile myelomonocytic leukemia (JMML)
Classical Hodgkin lymphoma (cHL) Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Epithelioid sarcoma Ewing sarcoma Hepatoblastoma Neuroblastoma
Osteosarcoma Rhabdomyosarcoma Wilms tumor

Transplant and Immune Effector Cells (IECs)
Stem cell mobilization Allogeneic HSCT Autologous HSCT Chimeric antigen receptor T cells (CAR-T)
Graft versus host disease (GVHD) Hepatic veno-occlusive disease (VOD/SOS)

Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Acquired thrombotic thrombocytopenic purpura (aTTP) Antiphospholipid antibody syndrome (APLAS) Congenital thrombotic thrombocytopenic purpura (cTTP)
Heparin-induced thrombocytopenia (HIT) Hereditary hemorrhagic telangiectasia (HHT) Inherited coagulopathy Inherited thrombophilia
Thrombotic microangiopathy (TMA) Venous thromboembolism (VTE)
Cytopenias
Aplastic anemia Autoimmune cytopenia Immune thrombocytopenia (ITP) Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
Atypical hemolytic uremic syndrome (aHUS) Warm autoimmune hemolytic anemia (WAIHA) Cold agglutinin disease (CAD) Paroxysmal nocturnal hemoglobinuria (PNH)
Pyruvate kinase deficiency (PKD) Beta thalassemia Sickle cell anemia
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include:

Additional possibilities for this project may include:

  • Creating synopses of pivotal clinical trials and regimens
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.


Retrieved from "https://hemonc.org/w/index.php?title=Main_Page&oldid=86694"